Activity of novobiocin against methicillin-resistantstaphylococcusaureus

Thomas J. Walsh, Sharon L. Hansen, Beverly A. Tatem, Francois Auger, Harold C. Standiford

Research output: Contribution to journalArticlepeer-review

Abstract

As infections due to methicillin-resistantStaphylococcus aureus become increasingly prevalent, newer alternative antibiotics, especially those which are orally administered, will be required. In order to provide anm-vitro basis for selecting alternative antibiotics, we studied the susceptibility of 103 strains of methicillin-resistantStaph aureus from seven institutions to oral antimicrobial agents. Novobiocin, nfampicin, and tnmethoprim-sulphamethoxazole had excellentin-vitro activity against virtually all strains of methicillin-resistantStaph aureus. The MIC90 and MBC90 of novobiocin against methicillin-resistantStaph aureus were 0-25 mg/1. Since previously reported achievable serum levels with oral novobiocin are 100 to 200 times its MIC90 against methicillin-resistant Staph. aureus, novobiocin should be evaluated further for combination therapy with nfampicin or trimethopnm-sulphamethoxazole.

Original languageEnglish (US)
Pages (from-to)435-440
Number of pages6
JournalJournal of Antimicrobial Chemotherapy
Volume15
Issue number4
DOIs
StatePublished - Apr 1985

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Activity of novobiocin against methicillin-resistantstaphylococcusaureus'. Together they form a unique fingerprint.

Cite this